Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Invest Ophthalmol Vis Sci. 2010 Jan;51(1):249-54. doi: 10.1167/iovs.09-3880. Epub 2009 Jul 30.
PURPOSE: Although primary congenital glaucoma (PCG)-associated CYP1B1 mutations in the heterozygous state have been evaluated for association with primary open-angle glaucoma (POAG) in several small studies, their contribution to the occurrence of POAG is still controversial. The present study was conducted to determine whether heterozygous functionally characterized CYP1B1 mutations are associated with the disease in a large cohort of German patients with POAG. METHODS: The frequency of CYP1B1 variants on direct sequencing of the entire coding region was compared in 399 unrelated German patients with POAG (270, POAG; 47, JOAG; and 82, NTG) and 376 control subjects without any signs of glaucoma on ophthalmic examination. In vitro functional assays were performed and relative enzymatic activity of the CYP1B1 variants embedded in their respective background haplotypes and not previously unambiguously classified were determined, to assess their possible causative role. RESULTS: Apart from known polymorphic variants, 11 amino acid substitutions in CYP1B1 reported before, both in PCG and POAG cases, were identified. After in vitro functional assay, variants P52L and R368H showed marked reduction of activity, confirming their role as loss-of-function mutations similar to previously determined variants G61E, N203S, and G329V. In contrast, variants G168D, A443G, and A465V showed no relevant effects and were thus classified as polymorphisms. Overall, seven functionally impaired variants were present in 13 (3.6%) patients and in 1 (0.2%) control subject (P = 0.002, OR = 5.4). Reanalysis of previous studies reporting CYP1B1 mutations in patients with POAG based on updated functional validation showed a significant excess of carriers among patients compared to controls (OR = 3.85; P = 2.3 x 10(-7)). CONCLUSIONS: Heterozygous CYP1B1 mutations with absent or reduced relative enzymatic activity can be considered a risk factor for POAG.
目的:尽管已在几项小规模研究中评估了杂合状态下与先天性青光眼(PCG)相关的 CYP1B1 突变与原发性开角型青光眼(POAG)之间的关联,但它们对 POAG 发生的贡献仍存在争议。本研究旨在确定在一个大型德国 POAG 患者队列中,杂合功能特征明确的 CYP1B1 突变是否与该疾病相关。
方法:比较了 399 例无青光眼迹象的德国 POAG 患者(270 例 POAG、47 例 JOAG 和 82 例 NTG)和 376 例无青光眼迹象的对照者中 CYP1B1 变体的直接测序频率。在体外进行功能测定,并确定在其各自背景单倍型中未明确分类的 CYP1B1 变体的相对酶活性,以评估其可能的因果作用。
结果:除了已知的多态性变体外,还鉴定了 CYP1B1 中以前报道的 11 种氨基酸取代,这些取代与 PCG 和 POAG 病例均有关。经体外功能测定,变体 P52L 和 R368H 显示活性明显降低,证实其作用与先前确定的变体 G61E、N203S 和 G329V 相似,为失功能突变。相比之下,变体 G168D、A443G 和 A465V 没有明显影响,因此被归类为多态性。总体而言,13 例(3.6%)患者和 1 例(0.2%)对照者中存在 7 种功能受损的变体(P = 0.002,OR = 5.4)。基于更新的功能验证对先前报道的 POAG 患者 CYP1B1 突变的研究进行重新分析显示,与对照组相比,患者中携带者明显过多(OR = 3.85;P = 2.3 x 10(-7))。
结论:无或降低的相对酶活性的杂合 CYP1B1 突变可被视为 POAG 的危险因素。
Invest Ophthalmol Vis Sci. 2009-7-30
Invest Ophthalmol Vis Sci. 2007-12
Life (Basel). 2025-3-3
Appl Clin Genet. 2019-10-4
Clin Ophthalmol. 2018-8-10
Hum Genet. 2018-3-19
Graefes Arch Clin Exp Ophthalmol. 2018-2